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bstract
he American College of Cardiology Foundation (ACCF),
ociety for Cardiovascular Angiography and Interventions,
ociety of Thoracic Surgeons, and the American Association
or Thoracic Surgery, along with key specialty and subspecialty
ocieties, conducted an appropriateness review of common
linical scenarios in which coronary revascularization is fre-
uently considered. The clinical scenarios were developed to
imic common situations encountered in everyday practice
nd included information on symptom status, extent of med-
cal therapy, risk level as assessed by noninvasive testing, and
oronary anatomy. Approximately 180 clinical scenarios were
eveloped by a writing committee and scored by a separate
echnical panel on a scale of 1 to 9. Scores of 7 to 9 indicate
hat revascularization was considered appropriate and likely to
mprove health outcomes or survival. Scores of 1 to 3 indicate
evascularization was considered inappropriate and unlikely to
mprove health outcomes or survival. The mid range (4 to 6)
ndicates a clinical scenario for which the likelihood that
oronary revascularization would improve health outcomes or
urvival was considered uncertain. For the majority of the
linical scenarios, the panel only considered the appropriate-
ess of revascularization irrespective of whether this was
ccomplished by percutaneous coronary intervention (PCI) or
oronary artery bypass graft surgery (CABG). In a select
ubgroup of clinical scenarios in which revascularization is
enerally considered appropriate, the appropriateness of PCI
nd CABG individually as the primary mode of revasculariza-
ion was considered.
In general, the use of coronary revascularization for patients
ith acute coronary syndromes and combinations of significant
ymptoms and/or ischemia was viewed favorably. In contrast,
evascularization of asymptomatic patients or patients with
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herapy were viewed less favorably. It is anticipated that these
esults will have an impact on physician decision making and
atient education regarding expected benefits from revascular-
zation and will help guide future research.
reface
he publication of appropriateness criteria reflects one of
everal ongoing efforts by the ACCF and its partners to assist
linicians caring for patients with cardiovascular diseases to
eliver high-quality cardiovascular care. The American College
f Cardiology (ACC)/American Heart Association (AHA)
ractice guidelines provide a foundation for summarizing
vidence-based cardiovascular care and, when evidence is
acking, provide expert consensus opinion that is approved in
eview by the ACCF and AHA. However, in many areas,
arked variability remains in the use of cardiovascular proce-
ures, raising questions of over- or under-use. One reason for
his variability is a paucity of large randomized clinical trials
onducted assessing the value of technology for specific pa-
ients, including cardiac imaging, catheterization, and coronary
evascularization. As such, there are many instances in practice
here the guidelines provide no recommendation, or alterna-
ively, a Level C recommendation (expert opinion). For other
reas, evidence is available but variability in clinical practice
emains. In either case, appropriateness criteria provide practical
ools to measure this variability to examine utilization patterns.
Appropriateness criteria are developed to serve as a supple-
ent to ACC/AHA guideline documents. Appropriateness
riteria are designed to examine the use of diagnostic and
herapeutic procedures to support efficient use of medical
esources during the pursuit of quality medical care. The
rocess of appropriateness criteria development has been de-
ned previously (1). Briefly, the appropriateness criteria writing
roup combines specific clinical characteristics to create proto-
ypical patient scenarios. These scenarios are then provided to
separate technical panel for appropriateness rating. The
echnical panel is created from nominations given by multiple
elevant professional societies and provider-led organizations as
ell as from health policy and payer communities. To preserve
bjectivity, the technical panels are created so as to not include
majority of individuals whose livelihood is tied to the
echnology under study.
In making its appropriateness determinations, the technical
anel is provided with summaries of the relevant evidence from
he medical literature and practice guidelines. They are then
sked first individually and then collectively to assess the
enefits and risks of a test or procedure in the context of the
otential benefits to patients’ outcomes and an implicit under-
tanding of the associated resource use and costs. After the
anking process, the final appropriateness ratings are summa-
ized using an established rigorous methodology (2).
Appropriateness criteria are based on current understanding
f the technical capabilities and potential patient benefits of the irocedures examined. Future evidence development may re-
uire these ratings to be updated. The appropriateness criteria
re also developed to identify common clinical scenarios—but
hey cannot possibly include every conceivable clinical situa-
ion. Thus, some patients seen in clinical practice are not
epresented in these appropriateness criteria or have additional
xtenuating features compared with the clinical scenarios
resented. Additionally, although appropriateness criteria in-
ications and ratings are shaped by the practice guidelines, the
ppropriateness criteria often contain more detailed scenarios
han the more generalized situations covered in clinical practice
uidelines, and thus, subtle differences between these 2 guid-
nce tools is possible.
Finally, appropriateness criteria are intended to assist
atients and clinicians, but are not intended to diminish the
cknowledged difficulty or uncertainty of clinical decision
aking and cannot act as substitutes for sound clinical
udgment and practice experience. Rather, the aim of these
riteria is to allow assessment of utilization patterns for a
est or procedure. Comparing utilization patterns across a
arge subset of provider’s patients can allow for an assess-
ent of a provider’s management strategies with those of
is/her peers. The ACCF and its collaborators believe that an
ngoing review of one’s practice using these criteria will help
uide a more effective, efficient, and equitable allocation of
ealth care resources, and ultimately, better patient outcomes.
In developing these appropriateness criteria for coronary
evascularization, the technical panel was asked to assess
hether coronary revascularization for each indication was
ppropriate, uncertain, or inappropriate using the following
efinition of appropriateness:
Coronary revascularization is appropriate when the ex-
ected benefits, in terms of survival or health outcomes
symptoms, functional status, and/or quality of life) exceed
he expected negative consequences of the procedure.
The technical panel scored each indication on a scale
rom 1 to 9 as follows:
Appropriate: Score 7 to 9
Appropriate for the indication provided, meaning coro-
ary revascularization is generally acceptable and is a rea-
onable approach for the indication and is likely to improve
he patients’ health outcomes or survival.
Uncertain: Score 4 to 6
Uncertain for the indication provided, meaning coronary
evascularization may be acceptable and may be a reasonable
pproach for the indication but with uncertainty implying
hat more research and/or patient information is needed to
urther classify the indication.
Inappropriate: Score 1 to 3
Inappropriate for the indication provided, meaning cor-
nary revascularization is not generally acceptable and is not
reasonable approach for the indication and is unlikely tomprove the patients’ health outcomes or survival.
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ories is somewhat arbitrary and that the numeric designations
hould be viewed as a continuum. Since some diversity in
linical opinions for particular clinical scenarios will exist or
vailable research is limited or conflicting, scores in the
ntermediate level of appropriateness are labeled “uncertain.”
his identifies the need for targeted investigations to clarify the
est therapy in these circumstances. It is anticipated that these
ppropriateness criteria will require updates as further data are
enerated and information from the implementation of these
riteria accumulates.
To prevent bias in the scoring process, the technical panel
as deliberately comprised of physicians with varying perspec-
ives on coronary revascularization and not comprised solely of
xperts (e.g., interventional cardiologists or cardiovascular sur-
eons) in the particular procedure under evaluation. Such
xperts, while offering important clinical and technical insights,
ight have a natural tendency to rate the indications within
heir specialty as more appropriate than nonspecialists. In
ddition, care was taken in providing objective, nonbiased
nformation, including national practice guidelines and a broad
ange of key references, to the technical panel.
We are grateful to the technical panel, a professional
roup with a wide range of skills and insights, for their
houghtful and thorough deliberation of the merits of
oronary revascularization for various indications. In addi-
ion to our thanks to the technical panel for their dedicated
ork and review, we would like to offer special thanks to the
any individuals who provided a careful review of the draft
ndications: to Peggy Christiansen, the ACCF librarian, for
er comprehensive literature searches; to Karen Caruth,
ho continually drove the process forward; to Lindsey Law
nd Kennedy Elliott, who helped map these criteria with
xisting ACC/AHA practice guidelines; and to Manesh
atel, MD, the chair of the writing committee, for his
edication, insight and leadership.
Frederick A. Masoudi, MD, MSPH, FACC
Moderator, Coronary Revascularization Technical Panel
Ralph G. Brindis, MD, MPH, FACC, FSCAI
Chair, Appropriateness Criteria Task Force
ntroduction
his report addresses the appropriateness of coronary revas-
ularization. The increasing prevalence of coronary artery
isease (CAD), advances in surgical and percutaneous
echniques for revascularization as well as concomitant
edical therapy for CAD, and the costs of revascularization
ave resulted in heightened interest regarding the appropri-
teness of coronary revascularization. Clinicians, payers, and
atients are interested in the specific benefits of revascular-
zation. Importantly, inappropriate use of revascularization
ay be potentially harmful to patients and generate unwar-
anted costs to the health care system, whereas appropriate
rocedures should likely improve patients’ clinical outcomes. bAll prior appropriateness criteria publications from the
CCF and collaborating organizations have reflected an
ngoing effort to critically and systematically create, review,
nd categorize the appropriateness of certain cardiovascular
iagnostic tests. This document presents the first attempt to
evelop appropriateness criteria for therapeutic procedures:
n this case, 2 distinct approaches to coronary artery revas-
ularization. This is an important shift to the explicit
onsideration of the potential benefits and risks of a thera-
eutic procedure. This document presents the results of this
ffort, but it is critical to understand the background and
cope of this document before interpreting the rating tables.
ethods
riefly, this process combines evidence-based medicine, guide-
ines, and practice experience by engaging a technical panel in a
odified Delphi exercise as previously described by RAND (2).
ndication Development
he writing group for the coronary revascularization indi-
ations was comprised of members from the relevant pro-
essional societies including both practicing interventional
ardiologists and a cardiothoracic surgeon. Recognizing
ariability in many patient factors, local practice patterns,
nd a lack of data comparing PCI with CABG in all
ossible clinical scenarios, the technical panel was asked to
ate the majority of clinical indications only for the appro-
riateness of revascularization and not to distinguish be-
ween the specific modes of revascularization (i.e., PCI
ersus CABG). In addition, the writing group identified
ndications for patients with advanced coronary disease and
ymptoms, where revascularization is generally considered
o be appropriate. In this section, PCI and CABG were
ndependently evaluated for appropriateness.
Once the indications were drafted, reviewers from all
articipating collaborators and stakeholders, including car-
iovascular and surgical societies, provided feedback regard-
ng the clinical indications for coronary revascularization.
hese comments led to substantial improvements and
hanges in the clinical scenarios.
cope of Indications
he indications contained in this report are purposefully
road and intended to represent the most common patient
cenarios for which coronary revascularization is considered.
he development of these clinical scenarios re-emphasized
o the writing group the complexity of the decision-making
rocess for revascularization and the number of variables
hat inform this decision. The writing group estimated that
ver 4,000 separate clinical scenarios would be required to
ncorporate all permutations of these variables. However,
roviding that level of granularity to this framework would
e cumbersome and likely degrade the purpose of these
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eveloped considering the following common variables:
. The clinical presentation (e.g., acute coronary syndrome,
stable angina, and so on);
. Severity of angina (asymptomatic, Canadian Cardiovas-
cular Society [CCS] Class I, II, III, or IV);
. Extent of ischemia on noninvasive testing and the
presence or absence of other prognostic factors, such as
congestive heart failure (CHF), depressed left ventricular
function, or diabetes;
. Extent of medical therapy; and
. Extent of anatomic disease (1-, 2-, 3-vessel disease, with
or without proximal left anterior descending artery
[LAD] or left main coronary disease).
The clinical indications developed include coronary anat-
my, as this is the focus of much of the previous literature
n coronary revascularization. However, the writing group
ecognizes that for everyday patient care, symptom status,
schemic burden, and level of medical therapy often play a
ritical role in decision making even before the coronary
natomy has been defined by angiography.
Please note that the indications focus on revascularization,
ercutaneous or surgical, and therefore do not address diag-
ostic catheterization or coronary angiography. Additionally,
he clinical scenarios presented are not inclusive of every
ossible clinical situation. For example, the use of coronary
evascularization for patients with multivessel disease including
or more occluded vessels and clinical symptoms or ischemia
as not included as a separate indication since other variations
f multivessel disease are present.
anel Selection
takeholders were given the opportunity to participate in
he appropriateness criteria process by submitting nominees
rom their organizations through a call for nominations
nnounced in the summer of 2006. From this list of
ominees, the task force and writing group selected techni-
al panel members to ensure an appropriate balance with
espect to expertise. The 17-member technical panel was
omposed of 4 interventional cardiologists, 4 cardiovascular
urgeons, 8 members representing cardiologists, other phy-
icians who treat patients with cardiovascular disease, health
utcome researchers, and 1 medical officer from a health plan.
ating Process and Scoring
he panel members first rated indications independently.
hen the panel met for a discussion of each indication.
fter the face-to-face discussion, panel members then
ndependently provided their final scores for each indica-
ion. Each panel member had equal weight in producing the
nal result for the indications and was not forced into
onsensus. For each indication, the median numerical score
as determined.At the face-to-face meeting, each panelist received a
ersonalized rating form that indicated his/her rating for
ach indication and the distribution of deidentified ratings
f other members of the panel. In addition, the moderator
eceived a summary rating form with similar information
including panelist identification), along with other statistics
eflecting the level of agreement among panel members.
he level of agreement among panelists, as defined by
AND, was analyzed for each indication based on the
IOMED rule for a panel of 14 to 16 (a simplified RAND
ethod for determining disagreement) (2). Per the
IOMED definition, agreement was defined as an indica-
ion where 4 or fewer panelists’ ratings fell outside the
-point region containing the median score. Disagreement
as defined as a situation where at least 5 panelists’ ratings
ell in both the appropriate and the inappropriate categories.
ecause the panel had 17 representatives, which exceeded
he 16 addressed in this rule, an additional level of agree-
ent analysis as described by RAND was performed that
xamines the interpercentile range compared to interpercen-
ile range adjusted for symmetry (2). This information was
sed by the moderator to guide the panel’s discussion by
ighlighting areas of differences among the panelists.
eneral Assumptions
pecific assumptions are provided that were considered by
he technical panel in rating the relevant clinical indications
or the appropriateness of revascularization:
1. Each clinical indication includes the patient’s clinical
status/symptom complex, ischemic burden by noninva-
sive functional testing when presented, burden of cor-
onary atherosclerosis as determined by angiography,
and intensity of medical therapy in the determination of
the appropriateness of coronary revascularization.
2. Assume coronary angiography has been performed
when these findings are presented in the clinical indi-
cations. The panel should rate the appropriateness of
revascularization based upon the clinical features and
coronary findings, and not the appropriateness of diag-
nostic coronary angiography.
3. Assume left main coronary artery stenosis (greater than or
equal to 50% luminal diameter narrowing) or proximal
LAD stenosis (greater than or equal to 70% luminal
diameter narrowing) is not present unless specifically
noted. Assume no other significant coronary artery steno-
ses are present except those noted in the clinical scenario.
4. The clinical scenarios should be rated based on the
published literature regarding the risks and benefits of
percutaneous and surgical coronary revascularization.
Note that specific patient groups not well represented in
the literature are not presented in the current clinical
scenarios. However, the writing group recognizes that
decisions about coronary artery revascularization in
such patients are frequently required. Examples of such
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advanced age.
5. Clinical outcome is related to the extent of coronary
artery disease (Table A) (3). Based on this observation
and clinical guideline recommendations regarding “bor-
derline” angiographic stenoses (50% to 60%) in epicar-
dial (non-left main) locations, a significant coronary
stenosis for the purpose of the clinical scenarios is
defined as:
• greater than or equal to 70% luminal diameter
narrowing, by visual assessment, of an epicardial
stenosis measured in the “worst view” angiographic
projection.
• greater than or equal to 50% luminal diameter
narrowing, by visual assessment, of a left main
stenosis measured in the “worst view” angiographic
projection.
6. All patients are receiving standard care, including
guideline-based risk factor modification for primary or
secondary prevention in cardiovascular patients unless
specifically noted (5–9).
7. Despite the best efforts of the clinician, all patients may
not achieve target goals for risk factor modification.
However, a plan of care to address risk factors is
assumed to be occurring in patients represented in the
indications. For patients with chronic stable angina, the
writing group recognizes that there is a wide variance in
the medical therapy for angina. The specific definition
of maximal anti-ischemic medical therapy is presented
in the definition section.
8. Operators performing percutaneous or surgical revascu-
larization have appropriate clinical training and experi-
ence and have satisfactory outcomes as assessed by
able A. CAD Prognostic Index
Extent of CAD
Prognostic
Weight
(0–100)
5-Year
Survival Rate
(%)*
-vessel disease, 75% 23 93
1-vessel disease, 50% to 74% 23 93
-vessel disease, 95% 32 91
-vessel disease 37 88
-vessel disease, both 95% 42 86
-vessel disease, 95% proximal LAD 48 83
-vessel disease, 95% LAD 48 83
-vessel disease, 95% proximal LAD 56 79
-vessel disease 56 79
-vessel disease, 95% in at least 1 63 73
-vessel disease, 75% proximal LAD 67 67
-vessel disease, 95% proximal LAD 74 59
Assuming medical treatment only. CAD indicates coronary artery disease; LAD, left anterior
escending coronary artery. From Califf RM, Armstrong PW, Carver JR, et al. Task Force 5.
tratification of patients into high-, medium-, and low-risk subgroups for purposes of risk factor
anagement. J Am Coll Cardiol. 1996;27:964–1047 (4).quality assurance monitoring (10–12). p9. Revascularization by either percutaneous or surgical
methods is performed in a manner consistent with
established standards of care (10–12).
0. In the clinical scenarios, no unusual extenuating cir-
cumstances exist (such as inability to comply with
antiplatelet agents, do not resuscitate status, patient
unwilling to consider revascularization, technically not
feasible to perform revascularization, or comorbidities
likely to markedly increase procedural risk substan-
tially), unless specifically noted.
efinitions
complete set of definitions of terms used throughout the
ndication set are listed in Appendix A. These definitions
ere provided and discussed with the technical panel prior
o ratings of indications.
aximal Anti-Ischemic Medical Therapy
s previously stated, the indications assume that patients
re receiving risk factor modification according to guideline-
ased recommendations. For the purposes of the clinical
cenarios presented, maximal antianginal medical therapy
s defined as the use of at least 2 classes of therapies to
educe anginal symptoms.
tress Testing and Risk of Findings on
oninvasive Testing
tress testing is commonly used for both diagnosis and risk
tratification of patients with coronary artery disease. Using
riteria defined for traditional exercise stress tests (13):
Low-risk stress test findings: associated with a cardiac
mortality of less than 1% per year;
Intermediate-risk stress test findings: associated with a
1% to 3% per year cardiac mortality;
High-risk stress test findings: associated with a greater
than 3% per year cardiac mortality.
Examples of findings from noninvasive studies and their
ssociated level of risk for cardiac mortality are presented in
able A2 (12). As noted in the footnote to this table, for
ertain low-risk findings, there may be additional findings
hat alter the assessment of risk, but these relationships have
ot been well studied. Implicit in these risk definitions is a
easure of the amount of myocardium at risk, or ischemic
yocardium. For the purpose of the clinical indications for
oronary revascularization, stress test findings are presented
y these risk criteria. For patients without stress test
ndings, please refer to the note below on invasive methods
f determining hemodynamic significance. Assume that
hen prior testing (including an imaging procedure) is
eferenced in an indication, the testing was performed
orrectly and with sufficient quality so as to produce a
eaningful and accurate result within the limits of the testerformance.
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ocument, patients with both typical and atypical angina are
lassified by the feature of the CCS grading system pre-
ented in Table B. Patients with noncardiac chest pain
hould be considered to be asymptomatic.
igh-Risk Features for Short-Term Risk of Death or
onfatal MI for UA/NSTEMI (15)
t least 1 of the following:
History—Accelerating tempo of ischemic symptoms in
preceding 48 hours
Character of pain—Prolonged ongoing (greater than 20
minutes) rest pain
Clinical findings
X Pulmonary edema, most likely due to ischemia
X New or worsening mitral regurgitation murmur
X S3 or new/worsening rales
X Hypotension, bradycardia, tachycardia
X Age greater than 75 years
Electrocardiogram
X Angina at rest with transient ST-segment changes
greater than 0.5 mm
X Bundle-branch block, new or presumed new
X Sustained ventricular tachycardia
able B. Grading of Angina Pectoris by the Canadian
ardiovascular Society Classification System
lass I
rdinary physical activity does not cause angina, such as walking, climbing
stairs. Angina (occurs) with strenuous, rapid, or prolonged exertion at work
or recreation.
lass II
light limitation of ordinary activity. Angina occurs on walking or climbing
stairs rapidly, walking uphill, walking or stair climbing after meals or in cold,
or in wind, or under emotional stress, or only during the few hours after
awakening. Angina occurs on walking more than 2 blocks on the level and
climbing more than one flight of ordinary stairs at a normal pace and in
normal condition.
lass III
arked limitations of ordinary physical activity. Angina occurs on walking one
to two blocks on the level and climbing one flight of stairs in normal
conditions and at a normal pace.
lass IV
nability to carry on any physical activity without discomfort—anginal
symptoms may be present at rest.
rom Campeau L. Grading of angina pectoris [letter]. Circulation. 1976;54:522–3 (14). Copyright
976 American Heart Association, Inc. Reprinted with permission.Cardiac marker
X Elevated cardiac Troponin T, Troponin I, or crea-
tine kinase-MB (e.g., Troponin T or I greater than
0.1 ng per ml)
bbreviations
ABG  coronary artery bypass grafting
AD  coronary artery disease
CS  Canadian Cardiovascular Society
CT  cardiac computed tomography
HF  congestive heart failure
CG  electrocardiogram
FR  fractional flow reserve
F  heart failure
VUS  intravascular ultrasound
AD  left anterior descending artery
IMA  left internal mammary artery
V  left ventricular
VEF  left ventricular ejection fraction
I  myocardial infarction
TG  nitroglycerin
CI  percutaneous coronary intervention
DA  patent ductus arteriosus
TEMI  ST-segment elevation myocardial infarction
A/NSTEMI  unstable angina/non–ST-segment eleva-
ion myocardial infarction
esults of Ratings
he final ratings for coronary revascularization (Tables 1 to 4)
re listed by indication sequentially as obtained from second
ound rating sheets submitted by each panelist. Figures dem-
nstrating trends in appropriateness rating by symptom status,
schemic risk, and method of revascularization are also presented.
There was generally less variation in ratings for the indica-
ions labeled as either appropriate or inappropriate, with 76%
nd 70%, respectively showing agreement as defined previously
n the Methods section. There was, however, greater variability
n the rating scores for indications defined as uncertain,
uggesting wide variation in opinion. Several indications failed
o meet the definition of agreement noted above. There were
o ratings where the panel held such opposing viewpoints that
he panel’s votes were determined to be in “disagreement” as
efined by the strict RAND definitions described previously in
he Methods section.
CT
*
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Indication
Appropriateness
Score (1–9)
1. ● STEMI A (9)*
● Less than or equal to 12 hours from onset of symptoms
● Revascularization of the culprit artery
2. ● STEMI A (9)
● Onset of symptoms within the prior 12 to 24 hours
● Severe HF, persistent ischemic symptoms, or hemodynamic or electrical instability present
3. ● STEMI I (3)
● Greater than 12 hours from symptom onset
● Asymptomatic; no hemodynamic instability and no electrical instability
4. ● STEMI with presumed successful treatment with fibrinolysis A (9)
● Evidence of HF, recurrent ischemia, or unstable ventricular arrhythmias present
● One-vessel CAD, presumed to be the culprit artery
5. ● STEMI with presumed successful treatment with fibrinolysis U (5)
● Asymptomatic; no HF or no recurrent ischemic symptoms, or no unstable ventricular arrhythmias
● Normal LVEF
● One-vessel CAD presumed to be the culprit artery
6. ● STEMI with presumed successful treatment with fibrinolysis A (8)
● Asymptomatic; no HF, no recurrent ischemic symptoms, or no unstable ventricular arrhythmias at time of presentation
● Depressed LVEF
● Three-vessel CAD
● Elective/semi-elective revascularization
7. ● STEMI with successful treatment of the culprit artery by primary PCI or fibrinolysis I (2)
● Asymptomatic; no HF, no evidence of recurrent or provokable ischemia or no unstable ventricular arrhythmias during
index hospitalization
● Normal LVEF
● Revascularization of a non-infarct related artery during index hospitalization
8. ● STEMI or NSTEMI and successful PCI of culprit artery during index hospitalization A (8)
● Symptoms of recurrent myocardial ischemia and/or high-risk findings on noninvasive stress testing performed after
index hospitalization
● Revascularization of 1 or more additional coronary arteries
9. ● UA/NSTEMI and high-risk features for short-term risk of death or nonfatal MI A (9)
● Revascularization of the presumed culprit artery
10. ● UA/NSTEMI and high-risk features for short-term risk of death or nonfatal MI A (9)
● Revascularization of multiple coronary arteries when the culprit artery cannot be clearly determined
11. ● Patients with acute myocardial infarction (STEMI or NSTEMI) A (8)
● Evidence of cardiogenic shock
● Revascularization of 1 or more coronary arteries
Subscripted numbers are a reflection of the continuum as per the appropriateness criteria methodology and should not be interpreted as “degrees of appropriateness or inappropriateness.”
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Appropriateness Score (1–9)
CCS Angina Class
Indication Asymptomatic I or II III or IV
12. ● One- or 2-vessel CAD without involvement of proximal LAD I (1)* I (2) U (5)
● Low-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
13. ● One- or 2-vessel CAD without involvement of proximal LAD I (2) U (5) A (7)
● Low-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
14. ● One- or 2-vessel CAD without involvement of proximal LAD I (3) U (5) U (6)
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
15. ● One- or 2-vessel CAD without involvement of proximal LAD U (4) A (7) A (8)
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
16. ● One- or 2-vessel CAD without involvement of proximal LAD U (6) A (7) A (8)
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
17. ● One- or 2-vessel CAD without involvement of proximal LAD A (7) A (8) A (9)
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
18. ● One- or 2-vessel CAD without involvement of proximal LAD † U (5) A (7)
● No noninvasive testing performed
19. ● One- or 2-vessel CAD with borderline stenosis “50% to 60%” † I (2) I (3)
● No noninvasive testing performed
● No further invasive evaluation performed (i.e., FFR, IVUS)
20. ● One- or 2-vessel CAD with borderline stenosis “50% to 60%” I (3) U (6) A (7)
● No noninvasive testing performed or equivocal test results present
● FFR less than 0.75 and/or IVUS with significant reduction in cross-sectional area
21. ● One- or 2-vessel CAD with borderline stenosis “50% to 60%” I (1) I (2) I (2)
● No noninvasive testing performed or equivocal test results present
● FFR or IVUS findings do not meet criteria for significant stenosis
22. ● Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses I (1) I (2) I (3)
● Low-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
23. ● Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses I (1) U (4) U (6)
● Low-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
24. ● Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses I (3) U (4) U (6)
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
25. ● Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses U (4) U (5) A (7)
● Intermediate-risk criteria on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
26. ● Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses U (4) U (5) A (7)
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
27. ● Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses U (5) A (7) A (8)
● High-risk criteria on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
28. ● One-vessel CAD involving the proximal LAD U (4) U (5) A (7)
● Low-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
29. ● One-vessel CAD involving the proximal LAD U (4) A (7) A (8)
● Low-risk findings on noninvasive testing
● Receiving maximal anti-ischemic medical therapy
T*
t
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Appropriateness Score (1–9)
CCS Angina Class
Indication Asymptomatic I or II III or IV
30. ● One-vessel CAD involving the proximal LAD U (4) U (6) A (7)
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
31. ● One-vessel CAD involving the proximal LAD U (5) A (8) A (9)
● Intermediate-risk findings on noninvasive testing
● Receiving maximal anti-ischemic medical therapy
32. ● One-vessel CAD involving the proximal LAD A (7) A (8) A (9)
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
33. ● One-vessel CAD involving the proximal LAD A (7) A (9) A (9)
● High-risk findings on noninvasive testing
● Receiving maximal anti-ischemic medical therapy
34. ● Two-vessel CAD involving the proximal LAD U (4) U (6) A (7)
● Low-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
35. ● Two-vessel CAD involving the proximal LAD U (5) A (7) A (8)
● Low-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
36. ● Two-vessel CAD involving the proximal LAD U (5) A (7) A (8)
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
37. ● Two-vessel CAD involving the proximal LAD U (6) A (7) A (9)
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
38. ● Two-vessel CAD involving the proximal LAD A (7) A (8) A (9)
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
39. ● Two-vessel CAD involving the proximal LAD A (8) A (9) A (9)
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
40. ● Three-vessel CAD (no left main) U (5) U (6) A (7)
● Low-risk findings on noninvasive testing including normal LV systolic function
● Receiving no or minimal anti-ischemic medical therapy
41. ● Three-vessel CAD (no left main) U (5) A (7) A (8)
● Low-risk findings on noninvasive testing including normal LV systolic function
● Receiving a course of maximal anti-ischemic medical therapy
42. ● Three-vessel CAD (no left main) A (7) A (7) A (8)
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
43. ● Three-vessel CAD (no left main) A (7) A (8) A (9)
● Intermediate risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
44. ● Three-vessel CAD (no left main) A (7) A (8) A (9)
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
45. ● Three-vessel CAD (no left main) A (8) A (9) A (9)
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
46. ● Three-vessel CAD (no left main) A (8) A (9)Q A (9)
● Abnormal LV systolic function
47. ● Left main stenosis A (9) A (9) A (9)Subscripted numbers are a reflection of the continuum as per the appropriateness criteria methodology and should not be interpreted as “degrees of appropriateness or inappropriateness.” †Indicates
hat the writing group felt the likelihood of the clinical scenario was so low that rating should not be performed.
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ode of Revascularization for High Severity of CAD
Indications 60 to 73)
ecognizing a large range of variability in revascularization
ethods often based upon patient factors and local practice
able 3. Patients With Prior Bypass Surgery (Without Acute Co
Indication
48. ● One or more stenoses in saphenous vein graft(s)
● Low-risk findings on noninvasive testing including norm
● Receiving no or minimal anti-ischemic medical therapy
49. ● One or more stenoses in saphenous vein graft(s)
● Low-risk findings on noninvasive testing including norm
● Receiving a course of maximal anti-ischemic medical th
50. ● One or more stenoses in saphenous vein graft(s)
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
51. ● One or more stenoses in saphenous vein graft(s)
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical th
52. ● One or more stenoses in saphenous vein graft(s)
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
53. ● One or more stenoses in saphenous vein graft(s)
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical th
54. ● One or more lesions in native coronary arteries without
● All bypass grafts patent and without significant disease
● Low-risk findings on noninvasive testing including norm
● Receiving no or minimal anti-ischemic medical therapy
55. ● One or more lesions in native coronary arteries without
● All bypass grafts patent and without significant disease
● Low-risk findings on noninvasive testing including norm
● Receiving a course of maximal anti-ischemic medical th
56. ● One or more lesions in native coronary arteries without
● All bypass grafts patent and without significant disease
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
57. ● One or more lesions in native coronary arteries without
● All bypass grafts patent and without significant disease
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical th
58. ● One or more lesions in native coronary arteries without
● All bypass grafts patent and without significant disease
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
59. ● One or more lesions in native coronary arteries without
● All bypass grafts patent and without significant disease
● High-risk finding on noninvasive testing
● Receiving a course of maximal anti-ischemic medical th
Subscripted numbers are a reflection of the continuum as per the appropriateness criteria metho
hat the writing group felt the likelihood of the clinical scenario was so low that rating should natterns, the majority of clinical indications were not intended co distinguish between the specific modes of revascularization
i.e., PCI versus CABG). However, the committee recognized
hat among patients with extensive or complex atherosclerosis
he mode of revascularization is also of interest when revascu-
arization is deemed appropriate. Therefore, Table 4 presents
omplex scenarios where the features of revascularization are
ry Syndromes)
Appropriateness Score (1–9)
CCS Angina Class
Asymptomatic I or II III or IV
ystolic function
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ethod independently of each other (such that each modality
ould receive separate scores based on each specific clinical
ndication).
ortality Risk
any of the known clinical factors that increase the risk of
evascularization are shared between CABG and percuta-
eous methods. For the indications presented below, the
uideline-based features of diabetes and depressed leftndications. These criteria should be useful to clinicians,
h
d
p
h
g
a
Subscripted numbers are a reflection of the continuum as per the appropriateness criteria methodolodvanced CAD
he clinical scenarios below specifically apply to patients
ith advanced CAD. It was assumed for these clinical
cenarios that all patients have unacceptable levels of symp-
oms despite appropriate medical therapy and evidence of
ntermediate- to high-risk findings on noninvasive testing.
n other words, the technical panel assumed that revascu-
arization is appropriate and focused on rating the merit of
he different modes with the intent of complete coronaryentricular systolic function were used to stratify patients. revascularization for each indication.
able 4. Method of Revascularization: Advanced Coronary Disease,* CCS Angina Greater Than or Equal to Class III, and/or
vidence of Intermediate- to High-Risk Findings on Noninvasive Testing
Appropriateness Score (1–9)
Indication
PCI
Appropriateness
Rating
CABG
Appropriateness
Rating
60. ● Two-vessel CAD with proximal LAD stenosis A (8)* A (8)
● No diabetes and normal LVEF
61. ● Two-vessel CAD with proximal LAD stenosis A (7) A (8)
● Diabetes
62. ● Two-vessel CAD with proximal LAD stenosis A (7) A (8)
● Depressed LVEF
63. ● Three-vessel CAD U (6) A (8)
● No diabetes and normal LVEF
64. ● Three-vessel CAD U (5) A (9)
● Diabetes
65. ● Three-vessel CAD U (4) A (9)
● Depressed LVEF
66. ● Isolated left main stenosis I (3) A (9)
● No diabetes and normal LVEF
67. ● Isolated left main stenosis I (3) A (9)
● Diabetes
68. ● Isolated left main stenosis I (3) A (9)
● Depressed LVEF
69. ● Left main stenosis and additional CAD I (3) A (9)
● No diabetes and normal LVEF
70. ● Left main stenosis and additional CAD I (2) A (9)
● Diabetes
71. ● Left main stenosis and additional CAD I (2) A (9)
● Depressed LVEF
72. ● Prior bypass surgery with native 3-vessel disease and failure of multiple bypass grafts A (7) U (6)
● LIMA remains patent to a native coronary artery
● Depressed LVEF
73. ● Prior bypass surgery with native 3-vessel disease and failure of multiple bypass grafts U (6) A (8)
● LIMA was used as a graft but is no longer functional
● Depressed LVEFgy and should not be interpreted as “degrees of appropriateness or inappropriateness.”iscussion
he ratings developed in this report provide an assessment
f the appropriateness of the use of coronary revasculariza-
ion for the clinical scenarios presented in each of theealth care facilities, third-party payers engaged in the
elivery of cardiovascular services, and most importantly,
atients. Experience with previous appropriateness criteria
as shown their value across a broad range of situations,
uiding care of individual patients, educating caregivers, and
ffecting policy decisions regarding reimbursement.
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hese indications are intended to provide guidance for
atients and clinicians. This approach is not intended to
iminish the acknowledged difficulty or uncertainty of
linical decision making. Appropriateness criteria are not
ubstitutes for sound clinical judgment and practice experi-
nce. The writing group recognizes that many patients seen
n clinical practice may not be represented in these appro-
riateness criteria or have extenuating features when com-
ared with the clinical scenarios presented. However, these
riteria provide a framework for discussions regarding re-
ascularization between patients and physicians.
Although these ratings provide a general assessment of
hen revascularization may or may not be likely to improve
ealth outcomes or survival, physicians and other stakehold-
rs should continue to acknowledge the pivotal role of
linical judgment in determining whether revascularization
s indicated for an individual patient. For example, the
ating of a revascularization indication as “uncertain” should
ot preclude a provider from performing a revascularization
rocedure when there are patient- and condition-specific
ata to support that decision. Uncertain indications require
ndividual physician judgment and understanding of the
atient to better determine the usefulness of the procedure
or a particular scenario. Indeed revascularization may be the
orrect treatment, if supported by mitigating characteristics
f the patient. Therefore, these criteria provide a framework
or discussion regarding revascularization upon which the
pecific clinical characteristics of an individual patient must
e superimposed. Ranking of an indication as uncertain (4
o 6) should not be viewed as excluding the use of
evascularization for such patients. Although it is consid-
red unlikely, an indication rated as “inappropriate” may in
are circumstances be the best therapy for an individual
atient. In contrast, a clinical situation rated as “appropri-
te” may not always represent reasonable practice in a
pecific patient with extenuating circumstances. Appropri-
teness also does not equate to medical necessity. Shared
hysician/patient decision making for many scenarios would
e expected and may result in the patient deferring coronary
evascularization while maintaining medical therapy.
These ratings are intended to evaluate the appropriate-
ess of specific patient scenarios to determine overall
atterns of care regarding revascularization. In situations
here there is substantial variation between the appropri-
teness rating and what the clinician believes is the best
ecommendation for the patient, further considerations or
ctions, such as a second opinion, may be appropriate.
oreover, it is not anticipated that all physicians or facilities
ill have 100% of their revascularization procedures deemed
ppropriate. However related to the overall patterns of care,
f the national average of appropriate procedure ratings is
0%, for example, and a physician or facility has only a 40%
ate of appropriate procedures, further examination of the
atterns of care may be warranted and helpful. peneral Themes in Appropriateness Criteria
or Revascularization
he purpose of coronary revascularization should be to
mprove health outcomes for the patients undergoing the
rocedure. As such, the technical panel was asked to rate
ach specific clinical indication with emphasis on the benefit
mparted to health outcomes (symptoms, functional status,
nd/or quality of life) or survival. It should be noted that the
ppropriateness Criteria for Coronary Revascularization
ontain no scenarios rated as “appropriate” that correlate
ith Class III recommendations in guideline documents.
ikewise, no “inappropriate” appropriateness criteria indi-
ations correlate with Class I guideline recommendations.
lthough multiple clinical and anatomic factors could have
een included in the clinical scenarios, the writing group
ocused on symptom status, degree of medical therapy,
xtent of ischemia by noninvasive testing, and finally, the
resence and location of significant coronary stenoses.
everal themes were identified in reviewing the results for the
ppropriateness Criteria for Coronary Revascularization.
cute Coronary Syndromes
he technical panel rated the majority of clinical scenarios
n these patients as appropriate for revascularization (Figure
). However, there were 2 notable exceptions that received
nappropriate ratings. First, in patients with STEMI pre-
enting greater than 12 hours from symptom onset without
ngoing symptoms of ischemia or clinical instability, imme-
iate revascularization was deemed inappropriate. By exten-
ion, this also implies that the need for immediate angiog-
aphy on presentation in such patients is unnecessary.
econd, after successful treatment of the culprit artery by
CI or fibrinolysis, revascularization of nonculprit arteries
efore hospital discharge in patients without clinical insta-
ility, with no evidence of recurrent or provokable ischemia,
nd with a normal LVEF was rated as inappropriate.
table Ischemic Heart Disease Without Prior CABG
n general, the presence of high-risk findings on noninvasive
esting, higher severity of symptoms, or an increasing
urden of CAD tended to elevate the rating to appropriate.
nappropriate ratings tended to cluster among groups re-
eiving no or minimal anti-ischemic treatment with low-
isk findings on noninvasive testing. Figures 2 to 4 illustrate
he interplay of these elements in determining appropriate-
ess. Four clinical scenarios (18 to 21) were included in
hich no functional testing was performed. Although the
bility to couple the anatomic findings from coronary
ngiography with the physiologic evaluation available from
he various diagnostic testing modalities is ideal, the writing
roup recognized that there are patients who undergo
ngiography without such testing. Revascularization was
ated appropriate in such patients if they had 1- or 2-vessel
isease with or without involvement of the proximal LAD
nd class III or IV angina. The level of medical therapy
atients were receiving in this particular scenario was not
s
t
d
t
p
i
s
a
i
s
F
*
t
d PCI,
u
F
(
A
u
543JACC Vol. 53, No. 6, 2009 Patel et al.
February 10, 2009:530–53 Appropriateness Criteria for Coronary Revascularizationpecifically considered and was thus left to the judgment of
he clinician. However, consistent with the pattern of care
eveloped in these appropriateness criteria, a trial of medical
herapy before performing revascularization may be appro-
riate in some patients. The remaining three scenarios
< 12 hrs
A
> 12 hrs
Cardiogenic shock
A
 Primary 
Reperfusion
Severe HF, persistent 
ischemia, hemodynamic or 
electrical instability present
A  I
 Asymptom
hemodynamic in
no electrical 
A
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High Risk features
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Hospitalization
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Reperfusion with 
lytic or PCI
Asymp
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testing perfor
Post - Index 
Hospitalization
igure 1. Acute Coronary Syndromes*
The fact that the use of coronary revascularization for a particular condition is liste
herapeutic modalities that may be equally effective. See the most current ACC/AHA
isease; HF, heart failure; I, inappropriate; LVEF, left ventricular ejection fraction;
ncertain; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.
igure 2. Appropriateness Ratings by Low-Risk Findings on Noninv
Patients Without Prior Bypass Surgery)indicates appropriate; CTO, chronic total occlusion; I, inappropriate; Int., intervention; Me
ncertain; and vz., vessel.nvolved patients found to have so-called intermediate
everity stenoses. The ratings in these settings reflect the
bility of additional evaluations performed in the catheter-
zation laboratory (such as FFR or IVUS) to identify
ignificant stenoses beyond their appearance by angiography
 STEMI
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zation of intermediate stenoses without further documen-
ation of significance by FFR or IVUS was rated as
nappropriate. Revascularization of such patients who dem-
nstrate abnormal IVUS or FFR findings and are highly
ymptomatic was deemed appropriate.
table Ischemic Heart Disease With Prior CABG
imilar to the pattern seen in patients without prior CABG,
he presence of high-risk findings on noninvasive testing,
igher severity of symptoms, or an increasing burden of
isease in either the bypass grafts or native coronaries
igure 3. Appropriateness Ratings by Intermediate-Risk Finding
Patients Without Prior Bypass Surgery)
CS indicates Canadian Cardiovascular Society, other abbreviations as in Figure 2.
igure 4. Appropriateness Ratings by High-Risk Findings on No
Patients Without Prior Bypass Surgery)bbreviations as in Figures 2 and 3.ended to increase the likelihood of an appropriate rating.
he only inappropriate ratings in patients with prior CABG
ere noted in patients receiving no or minimal anti-
schemic therapy or having low-risk findings on noninvasive
esting. More uncertain ratings occurred in this group of
atients, reflecting their higher complexity, higher risk, and
he limited availability of published evidence regarding
anagement outcome.
CI and CABG in Patients With Advanced CAD
n this group of ratings, it was assumed that revasculariza-
ion was necessary, and the technical panel rated the
Noninvasive Imaging Study and CCS Class I or II Angina
sive Imaging Study and CCS Class III or IV Anginas onninva
a
F
c
p
o
d
s
a
o
n
p
A
T
c
o
r
f
a
m
d
r
w
r
m
c
i
p
a
u
i
g
c
g
R
d
d
o
i
I
u
p
e
a
o
p
o
t
e
n
i
p
i
e
d
a
o
d
s
r
t
w
a
t
a
f
n
d
w
n
s
b
p
w
F
C LVEF,
545JACC Vol. 53, No. 6, 2009 Patel et al.
February 10, 2009:530–53 Appropriateness Criteria for Coronary Revascularizationppropriateness of the mode of revascularization (Table 4,
igure 5). CABG was rated as appropriate in all of the
linical scenarios developed, whereas PCI was rated appro-
riate only in patients with 2-vessel CAD with involvement
f the proximal LAD and uncertain in patients with 3-vessel
isease. For patients with left main stenosis and/or left main
tenosis and multivessel CAD, CABG was deemed to be
ppropriate and likely to improve the patients’ health
utcomes or survival. PCI for this patient group was deemed
ot to be a reasonable approach and unlikely to improve the
atients’ health outcomes or survival.
pplication of Criteria
here are many potential applications for appropriateness
riteria. Clinicians could use the ratings for decision support
r as an educational tool when considering the need for
evascularization. Moreover, these criteria could be used to
acilitate discussion with patients and or referring physicians
bout the need for revascularization. Facilities and payers
ay choose to use these criteria either prospectively in the
esign of protocols or pre-authorization procedures, or
etrospectively for quality reports. It is hoped that payers
ould use these criteria as the basis for the development of
ational payment management strategies to ensure that their
embers receive necessary, beneficial, and cost-effective
ardiovascular care, rather than for other purposes.
It is expected that services performed for appropriate
ndications will receive reimbursement. In contrast, services
erformed for inappropriate indications will likely require
dditional documentation to justify payment because of the
nique circumstances or the clinical profile that must exist
n such a patient. It is critical to emphasize that the writing
roup, technical panel, Appropriateness Task Force, and
linical community do not believe an uncertain rating is
rounds to deny reimbursement for revascularization.
ather, uncertain ratings are those in which the available
ata vary and many other factors exist that may affect the
ecision to perform or not perform revascularization. The
pinions of the technical panel often varied for these
igure 5. Method of Revascularization of Advanced Coronary Arter
ABG indicates coronary artery bypass grafting; LAD, left anterior descending artery;ndications, reflecting that additional research is needed. pndications with high clinical volume that are rated as
ncertain identify important areas for further research.
When evaluating physician or facility performance, ap-
ropriateness criteria should be used in conjunction with
fforts that lead to quality improvement. Prospective pre-
uthorization procedures, if put in place, are most effective
nce a retrospective review has identified a pattern of
otential inappropriate use. Because these criteria are based
n current scientific evidence and the deliberations of the
echnical panel, they should be used prospectively to gen-
rate future discussions about reimbursement, but should
ot be applied retrospectively to cases completed before
ssuance of this report or documentation of centers/
roviders performing an unexpectedly high proportion of
nappropriate cases as compared with their peers.
The writing group recognizes that these criteria will be
valuated during routine clinical care. To that end, specific
ata fields such as symptom status, presence or absence of
cute coronary syndrome, history of bypass surgery, extent
f ischemia on noninvasive imaging, CAD burden, and
egree of antianginal therapy are anticipated to provide
ufficient detail to determine individual appropriateness
atings. Since a reasonable and tolerated dose of antianginal
herapy may vary significantly among different patients, the
riting group recommends the presence of 2 classes of
ntianginal therapies as a minimum standard for medical
herapy.
The primary objective of this report is to provide guid-
nce regarding the suitability of coronary revascularization
or diverse clinical scenarios. As with previous appropriate-
ess criteria documents, consensus among the raters was
esirable, but an attempt to achieve complete agreement
ithin this diverse panel would have been artificial and was
ot the goal of the process. Two rounds of ratings with
ubstantial discussion among the technical panel members
etween the ratings did lead to some consensus among
anelists. However, further attempts to drive consensus
ould have diluted true differences in opinion among
ease
left ventricular ejection fraction; and PCI, percutaneous coronary intervention.y Disanelists and, therefore, was not undertaken.
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ions rated as appropriate would help ensure the equitable
nd efficient allocation of resources for coronary revascu-
arization. Review of appropriateness patterns may also
mprove understanding of regional variations in the use
f revascularization as highlighted in the Dartmouth
tlas Project (17). Further exploration of the indications
ated as “uncertain” will help generate the information
equired to further define the appropriateness of coronary
evascularization. Additionally, the criteria will need to
e updated with the publication of ongoing trials in
oronary revascularization and new clinical practice guidelines.
In conclusion, this document represents the current
nderstanding of the clinical benefit of coronary revas-
ularization with respect to health outcomes and survival.
t is intended to provide a practical guide to clinicians
nd patients when considering revascularization. As with
ther appropriateness criteria, some of these ratings will
equire research and further evaluation to provide the
reatest information and benefit to clinical decision
aking. Finally, it will be necessary to periodically assess
nd update the indications and criteria as technology
volves and new data and field experience becomes available.
ppendix A: Additional Coronary
evascularization Definitions
ngina/Chest Pain Classification
ngina is a syndrome typically noted to include discomfort
n the chest, jaw, shoulder, back, or arm that is aggravated
y exertion or emotional stress and relieved by nitroglycerin.
he quality of the discomfort, provoking factors, and
elieving factors are used to define typical, atypical, and
oncardiac chest pain. Atypical angina is generally defined
y 2 of the above 3 characteristics, and noncardiac chest
ain is generally defined as chest pain that meets 1 or none
f the above criteria. These definitions are represented in
able A1 presented below.
The writing group assumes that noninvasive assessments
f coronary anatomy (i.e., cardiac computed tomography,
ardiac magnetic resonance angiography) provide anatomic
nformation that is potentially similar to X-ray angiography.
able A1. Clinical Classification of Chest Pain
ypical angina (definite)
1) Substernal chest discomfort with a characteristic quality and duration that
is 2) provoked by exertion or emotional stress and 3) relieved by rest or NTG.
typical angina (probable)
Meets 2 of the above characteristics.
oncardiac chest pain
Meets one or none of the typical anginal characteristics.
odified from Diamond GA. A clinically relevant classification of chest discomfort. J Am Coll
ardiol. 1983;1:574–5 (18).owever, these modalities do not currently provide infor- iation on ischemic burden and are not assumed to be
resent in the clinical scenarios.
nvasive Methods of Determining
emodynamic Significance
he writing group recognizes that not all patients referred
or coronary angiography and revascularization will have
revious noninvasive testing. In fact, there are several
ituations in which patients may be appropriately referred
or coronary angiography based on symptom presentation
nd a high pre-test probability of CAD. In these settings,
here may be situations where angiography shows a coronary
arrowing of questionable hemodynamic importance in a
atient with symptoms that could be related to myocardial
schemia. In such patients, the use of additional invasive
easurements (such as fractional flow reserve or intravas-
ular ultrasound) at the time of diagnostic angiography may
e very helpful in further defining the need for revascular-
zation and substituted for stress test findings (Table A2).
ppendix B: Additional Methods
ee the earlier Methods section of the report for a descrip-
ion of panel selection, indication development, scope of
able A2. Noninvasive Risk Stratification
igh-Risk (greater than 3% annual mortality rate)
1. Severe resting left ventricular dysfunction (LVEF less than 35%)
2. High-risk treadmill score (score less than or equal to 11)
3. Severe exercise left ventricular dysfunction (exercise LVEF less than 35%)
4. Stress-induced large perfusion defect (particularly if anterior)
5. Stress-induced multiple perfusion defects of moderate size
6. Large, fixed perfusion defect with LV dilation or increased lung uptake
(thallium-201)
7. Stress-induced moderate perfusion defect with LV dilation or increased
lung uptake (thallium-201)
8. Echocardiographic wall motion abnormality (involving greater than two
segments) developing at low dose of dobutamine (less than or equal to
10 mg/kg/min) or at a low heart rate (less than 120 beats/min)
9. Stress echocardiographic evidence of extensive ischemia
ntermediate-Risk (1% to 3% annual mortality rate)
1. Mild/moderate resting left ventricular dysfunction (LVEF equal to 35% to
49%)
2. Intermediate-risk treadmill score (11 less than score less than 5)
3. Stress-induced moderate perfusion defect without LV dilation or increased
lung intake (thallium-201)
4. Limited stress echocardiographic ischemia with a wall motion abnormality
only at higher doses of dobutamine involving less than or equal to two
segments
ow-Risk (less than 1% annual mortality rate)
1. Low-risk treadmill score (score greater than or equal to 5)
2. Normal or small myocardial perfusion defect at rest or with stress*
3. Normal stress echocardiographic wall motion or no change of limited
resting wall motion abnormalities during stress*
Although the published data are limited, patients with these findings will probably not be at low
isk in the presence of either a high-risk treadmill score or severe resting left ventricular
ysfunction (LVEF  35%).ndications, and rating process.
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iterature Review
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